


Serial No. 10/694,845

PAGE 2
Docket No. 51630AUSC1AMENDMENTS TO THE CLAIMS

The below listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-11 (Cancelled).

Claim 12 (Amended). A compound of formula I,



wherein

R^1 and R^2 are, independently of one another, hydrogen, C_{1-6} alkyl, OR^7 , NR^7R^8 , CN, acyl, CO_2R^9 , $CONR^7R^8$ or $CSNR^7R^8$,

R^3 is a saturated or unsaturated C_{1-5} alkylene radical, which is optionally substituted in 1 to 4 places with OR^7 , $NR^{11}R^{12}$ or C_{1-4} alkyl and which are is optionally bridged with a methano, ethano or propano group,

R^4 is C_{1-4} alkyl substituted with $NR^{14}R^{15}$,

R^5 is hydrogen, halogen, OR^7 , C_{1-4} alkyl, CF_3 , or OCF_3 ,

or, R^4 and R^5 optionally together with 2 adjacent carbon atoms form a C_3 - C_4 alkylene moiety optionally substituted in one or two places with $NR^{14}R^{15}$,

~~R^5 and R^6 is are, independently of one another,~~ Hydrogen, halogen, OR^7 , C_{1-4} alkyl, CF_3 , or OCF_3 ,

R^7 , R^{18} and R^{19} are, independently of one another, Hydrogen, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl,

R^8 , R^{11} and R^{12} are, independently of one another, Hydrogen, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl, COR^{10} , CO_2R^{10} , $CONR^{18}R^{19}$ or $CSNR^{18}R^{19}$,

Serial No. 10/694,845

PAGE 3
Docket No. 51630AUSC1 R^9, R^{10}

and R^{20} are, independently of one another, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl,

R^{14} and R^{15} are, independently of one another, Hydrogen, CO_2R^{20} or C_{1-6} alkyl, which optionally is substituted with halogen, hydroxy, C_{1-4} alkoxy, nitro, amino, C_{1-6} alkyl, trifluoromethyl, carboxyl, cyano, carboxamido, C_{3-7} cycloalkyl, indanyl, 1,2,3,4-tetrahydronaphthyl, C_{6-10} aryl, wherein the aryl radical is optionally substituted with halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkyl, CF_3 , NO_2 , NH_2 , $N(C_{1-4} \text{ alkyl})_2$ or carboxyl, ~~or~~ and

n is 0, 1 or 2,

or a tautomeric or isomeric form of or a salt of a compound of formula I.


Claim 13 (Previously Presented): A compound according to claim 12, in which R^3 is a C_{1-5} alkylene radical, which is optionally bridged with a methano, ethano or propano group.

Claim 14 (Previously Presented): A compound according to claim 12, in which R^1 and R^2 is hydrogen.

Claim 15 (Amended): A pharmaceutical composition comprising an effective amount of a compound according to claims 12, and a pharmaceutically acceptable vehicle or adjuvant.

Claims 16-18 (Cancelled).

Claim 19 (Amended): A compound of formula I,



wherein

R^1 and R^2 are, each independently, hydrogen or C_{1-6} alkyl,

Serial No. 10/694,845

PAGE 4
Docket No. S1630AUSC1

R^3 is a saturated or unsaturated C_{1-5} alkylene radical, which is optionally substituted in 1 to 4 places with OR^7 , $NR^{11}R^{12}$ or C_{1-4} alkyl and which are is optionally bridged with a methano, ethano or propano group,

R^4 is C_{1-4} alkyl, substituted with $NR^{14}R^{15}$,

R^5 is hydrogen, halogen, OR^7 , C_{1-4} alkyl, CF_3 , or OCF_3 ,

or, R^4 and R^5 optionally together with 2 adjacent carbon atoms form a C_3 - C_4 alkylene moiety optionally substituted in one or two places with $NR^{14}R^{15}$,

R^5 and R^6 is are, independently of one another, Hydrogen, halogen, OR^7 , C_{1-4} alkyl, CF_3 , or OCF_3 ,

R^7 , R^{18}
and R^{19} are, independently of one another, Hydrogen, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl,

R^8 , R^{11}
and R^{12} are, independently of one another, Hydrogen, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl, COR^{10} , CO_2R^{10} , $CONR^{18}R^{19}$ or $CSNR^{18}R^{19}$,

R^9 , R^{10}
and R^{20} are, independently of one another, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl,

R^{14} and R^{15} are, independently of one another, Hydrogen, CO_2R^{20} or C_{1-6} alkyl, which optionally is substituted with halogen, hydroxy, C_{1-4} alkoxy, nitro, amino, C_{1-6} alkyl, trifluoromethyl, carboxyl, cyano, carboxamido, C_{3-7} cycloalkyl, indanyl, 1,2,3,4-tetrahydronaphthyl, C_{6-10} aryl, wherein the aryl radical is optionally substituted with halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkyl, CF_3 , NO_2 , NH_2 , $N(C_{1-4} \text{ alkyl})_2$ or carboxyl, ~~or~~ and

n is 0, 1 or 2,

or a tautomeric or isomeric form of or a salt of a compound of formula I.

Claim 20 (Previously Presented): A compound according to claim 19, wherein R^3 is a C_{1-5} alkylene radical, which is optionally bridged with a methano, ethano or propane group.

Claim 21 (Cancelled).

Serial No. 10/694,845

PAGE 5
Docket No. 51630AUSC1

Claim 22 (New): A compound according to claim 12, which is selected from the group consisting of:

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)methyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-7-(3-chlorobenzylamino)methyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-7-(3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-[1-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)propyl]-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-7-[1-(3-chlorobenzylamino)propyl]-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)ethyl-8-chloro-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-8-chloro-7-(3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)-1,2,3,3a,7,8,9,10b-octahydro-dicyclopenta[c,g]quinoline, and

4-amino-7-(3-chlorobenzylamino)methyl-1,2,3,3a,7,8,9,10b-octahydro-dicyclopenta[c,g]quinoline dihydrochloride.

Claim 23 (New): A pharmaceutical composition according to claim 15, in which R³ is a C₁₋₅ alkylene radical, which is optionally bridged with a methano, ethano or propano group.

Claim 24 (New): A pharmaceutical composition according to claim 15, in which R¹ and R² is hydrogen.

Claim 25 (New): A pharmaceutical composition according to claim 15, wherein the compound is selected from the group consisting of:

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)methyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

Serial No. 10/694,845

PAGE 6
Docket No. 51630AUSC1

4-amino-7-(3-chlorobenzylamino)methyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-7-(3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-[1-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)propyl]-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-7-[1-(3-chlorobenzylamino)propyl]-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)ethyl-8-chloro-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-8-chloro-7-(3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)-1,2,3,3a,7,8,9,10b-octahydro-dicyclopenta[c,g]quinoline, and

4-amino-7-(3-chlorobenzylamino)methyl-1,2,3,3a,7,8,9,10b-octahydro-dicyclopenta[c,g]quinoline dihydrochloride.